Long-Term Exposure to Low-Dose Prednisone With Abiraterone Acetate for mCRPC
May 21st 2015Leonard Gomella, MD, professor, Jefferson University, physician, chair, Department of Urology, director, Kimmel Cancer Center Network, discusses results from a study that assessed the corticosteroid-associated adverse events with long-term exposure to low-dose prednisone given with abiraterone acetate to patients with metastatic castration-resistant prostate cancer (mCRPC).